The DEBBRAH trial (NCT04420598), is a phase 2 study evaluating T-DXd in patients with HER2-positive or HER2-low expressing (HER2-LE) advanced breast cancer and central nervous system (CNS) involvement, either brain metastasis or leptomeningeal carcinomatosis. This evidence concerns the gene ERBB2 and breast cancer.